You are viewing: US Cancer Diagnostics Market analysis
Part of: Cancer Diagnostics Market (Global)

The US Cancer Diagnostics Market was valued at $6403.3 Million in 2021 and projected to reach to $10633.4 Million by 2026, representing a compound annual growth rate of 10.7%. The US cancer diagnostics market is positioned for sustained growth through 2026, supported by increasing cancer incidence rates, aging demographics, and heightened awareness of early detection benefits.

US Cancer Diagnostics Market (2021-2026) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

US Cancer Diagnostics Market Trends and Insights

  • This robust expansion in the US reflects increasing cancer prevalence, rising demand for early detection technologies, and substantial investments in precision medicine infrastructure.
  • The US market benefits from advanced healthcare systems, high adoption rates of innovative diagnostic tools, and strong reimbursement frameworks that support market penetration. Driving growth in the US cancer diagnostics sector are technological advancements in molecular testing, liquid biopsy platforms, and AI-enabled imaging solutions.
  • The US healthcare landscape increasingly prioritizes personalized cancer treatment, which requires sophisticated diagnostic capabilities to identify tumor-specific mutations and biomarkers.
  • Between 2021 and 2026, the US market will continue to expand as healthcare providers and diagnostic laboratories invest in next-generation sequencing, immunohistochemistry, and companion diagnostics to improve patient outcomes and treatment efficacy..

Key Market Statistics

  • CAGR (2021-2026) 10.7% CAGR
  • Market Size, 2021 ~USD 6403.3 Million
  • Forecast, 2026 ~USD 10633.4 Million
  • Country US

US Cancer Diagnostics Market Overview

Market Valuation Growth :

The US cancer diagnostics market reached $6,403.3 million in 2021 and is forecast to expand to $10,633.4 million by 2026, driven by technological advancement and increased healthcare spending.

Strong CAGR Performance :

The US market is growing at 10.7% CAGR, slightly below the global rate of 11.5%, reflecting mature market dynamics but sustained demand for innovative diagnostic solutions.

Early Detection Demand :

Rising cancer prevalence in the US population is fueling demand for advanced early detection technologies, including liquid biopsies, genomic sequencing, and AI-powered imaging solutions.

Precision Medicine Investment :

Substantial US investments in precision medicine infrastructure and personalized treatment approaches are accelerating adoption of advanced diagnostic platforms across healthcare systems.

US Cancer Diagnostics Market Dynamics

  • Healthcare providers are increasingly adopting advanced diagnostic technologies to improve patient outcomes and reduce treatment costs.
  • The market will benefit from continued innovation in molecular diagnostics, immunoassays, and digital pathology solutions. Key growth drivers include expanded insurance coverage for precision diagnostics, integration of artificial intelligence in diagnostic workflows, and growing collaboration between diagnostic companies and healthcare institutions.
  • The US market's maturity enables rapid adoption of cutting-edge technologies, while regulatory frameworks support innovation.
  • Investment in cancer research and preventive care initiatives will further strengthen market expansion through 2026..

Market Ecosystem

logo-mobile

CANCER DIAGNOSTICS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
company logo
Develops molecular and tissue-based cancer diagnostic solutions, including companion diagnostics, PCR-based assays, next-generation sequencing (NGS), immunohistochemistry (IHC), and digital pathology for oncology applications. Enables early and accurate cancer detection, supports personalized treatment selection, improves diagnostic confidence, and enhances patient outcomes through precision medicine.
company logo
Develops advanced cancer diagnostic solutions, including molecular diagnostics, HPV testing, cervical cytology, breast imaging (3D mammography/tomosynthesis), biopsy systems, and digital pathology technologies for early cancer detection, diagnosis, and treatment guidance. Enables early and accurate cancer detection, improves screening and diagnostic accuracy, supports personalized treatment decisions, enhances workflow efficiency, and improves patient outcomes through comprehensive oncology diagnostics.
company logo
Provides molecular oncology testing, digital pathology, tissue diagnostics, flow cytometry, and NGS solutions for detecting cancer biomarkers, monitoring disease progression, and guiding targeted therapies. Delivers rapid and precise cancer diagnosis, improves laboratory efficiency, supports personalized oncology care, and enables informed treatment decisions.
company logo
Provides advanced imaging technologies, laboratory diagnostics, molecular testing, and AI-enabled solutions for cancer screening, diagnosis, staging, and therapy monitoring. Enhances early cancer detection, improves diagnostic precision, supports treatment planning, and streamlines oncology workflows.
company logo
Develops molecular diagnostic kits, sample preparation technologies, companion diagnostics, and NGS workflows for identifying cancer-related genetic mutations and biomarkers. Enables accurate biomarker detection, supports precision oncology, accelerates molecular testing, and improves patient stratification for targeted therapies.

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

Related Ecosystem

In Vitro Diagnostics

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Dna Microarrays
  • Assay Kits
  • Microarrays
Top Companies
  • ROCHE HOLDINGS AG
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation
  • Abbott Laboratories
  • Biomerieux s.a.

    Medical Devices

    Top Technologies
    • Polymerase Chain Reaction (PCR)
    • Magnetic Resonance Imaging (MRI)
    • Disposable Autoinjectors
    • Pulse Oximeters
    • Blood Pressure Monitors
    Top Companies
    • Medtronic plc
    • Abbott Laboratories
    • Stryker Corporation
    • Becton, Dickinson and Company
    • CONMED Corporation

      Key Takeaways

      • The US cancer diagnostics market is valued at $6,403.3 million in 2021 and will reach $10,633.4 million by 2026, growing at a 10.7% CAGR.
      • The US market is driven by increasing cancer incidence, demand for early detection, and adoption of precision medicine approaches.
      • Advanced diagnostic technologies including liquid biopsy, NGS, and AI-enabled imaging are reshaping the US cancer diagnostics landscape.
      • Strong US healthcare infrastructure, reimbursement policies, and R&D investments support sustained market expansion through 2026.

      Cancer Diagnostics Market Report Scope

      Report Metric Details
      Base Year 2021
      Fastest Growing Segment BREAST CANCER (Application)
      Forecast Period 2021-2026
      Growth Rate CAGR of 11.5% from 2021 to 2026
      Largest Segment HOSPITALS (End User)
      Market Size Base Year (Billions) ~USD 15.44 (2021)
      Revenue Forecast (Billions) ~USD 26.6 (2026)
      Segments Covered Product, Type, Technology, Application, End User

      US Cancer Diagnostics Market Report Segmentation

      5 segment dimensions are covered across the global market.

      By Product

      • Consumables
      • Instruments

      By Type

      • Antibodies
      • Biopsy Instruments
      • Cell Processors
      • Ct
      • Ct Systems
      • Flow Cytometry
      • Ihc
      • Imaging Instruments
      • Immunoassay
      • Ish
      • Kits & Reagents
      • Mammography
      • Mammography Systems
      • Microarray
      • Microarrays
      • Microarrays Instruments
      • Mri
      • Mri Systems
      • Ngs
      • Ngs Instruments
      • Nuclear Imaging
      • Nuclear Imaging Systems
      • Other Consumables
      • Other Ivd Technologies
      • Other Pathology-Based Instruments
      • Pathology-Based Instruments
      • Pcr
      • Pcr Instruments
      • Probes
      • Slide Staining Systems
      • Tissue Processing Systems
      • Ultrasound
      • Ultrasound Systems

      By Technology

      • Biopsies
      • Imaging Technologies
      • Ivd Testing

      By Application

      • Breast Cancer
      • Colorectal Cancer
      • Lung Cancer
      • Melanoma
      • Other Cancers

      By End User

      • Diagnostic Laboratories
      • Hospitals

      Target Audience

      • Diagnostic Device Manufacturers : Evaluate US market potential, competitive positioning, and growth opportunities to guide product development, commercialization strategies, and market expansion investments in cancer diagnostics.
      • Healthcare Providers & Hospital Systems : Understand market trends and technology adoption patterns to make informed procurement decisions, optimize diagnostic capabilities, and improve patient outcomes in cancer care delivery.
      • Investment & Private Equity Firms : Assess market size, growth trajectory, and investment opportunities in US cancer diagnostics companies to identify acquisition targets and portfolio optimization strategies.
      • Pharmaceutical & Biotech Companies : Leverage US market insights to align companion diagnostic development with treatment pipelines, understand reimbursement landscapes, and identify partnership opportunities.
      • Healthcare Consultants & Analysts : Access comprehensive US market data to support client advisory services, competitive analysis, market entry strategies, and long-term healthcare industry forecasting.

      Reasons to Buy this Report

      • Market Size & Growth Validation : Quantified US market data with precise valuations ($6.4B to $10.6B) and verified 10.7% CAGR enables accurate financial forecasting and investment decision-making for US-focused strategies.
      • Competitive Landscape Intelligence : Understand US-specific market dynamics, key players, and technology adoption patterns to identify competitive positioning opportunities and market entry strategies in America's mature healthcare sector.
      • Regulatory & Reimbursement Insights : Access US-specific regulatory environment analysis and insurance coverage trends that directly impact product commercialization, pricing strategies, and market penetration timelines.
      • Technology Adoption Trends : Identify which diagnostic technologies are gaining traction in US healthcare systems, including AI integration, liquid biopsies, and genomic testing adoption rates among providers and patients.
      • Strategic Investment Planning : Make informed decisions on R&D investments, partnerships, and market expansion in the US with detailed forecasts, growth drivers, and emerging opportunities through 2026.

      Frequently asked questions

      What is the current size of the US cancer diagnostics market?

      The US cancer diagnostics market was valued at $6,403.3 million in 2021 and is expected to reach $10,633.4 million by 2026.

      What is the projected growth rate for the US cancer diagnostics market?

      The US cancer diagnostics market is projected to grow at a compound annual growth rate (CAGR) of 10.7% from 2021 to 2026.

      What are the main drivers of growth in the US cancer diagnostics market?

      Key drivers include rising cancer prevalence, increased demand for early detection, adoption of precision medicine, technological advancements in molecular testing, and strong healthcare infrastructure and reimbursement policies in the US.

      Which diagnostic technologies are leading growth in the US market?

      Liquid biopsy platforms, next-generation sequencing (NGS), AI-enabled imaging solutions, immunohistochemistry, and companion diagnostics are among the leading technologies driving US market expansion.

      How does the US cancer diagnostics market compare to global trends?

      The US market grows at 10.7% CAGR, slightly below the global rate of 11.5%, but represents a significant portion of the global market due to advanced healthcare infrastructure and high diagnostic adoption rates.

      RESEARCH METHODOLOGY

      The study involved major activities in estimating the current market size for the Cancer Diagnostics  market. Exhaustive secondary research was done to collect information on the Cancer Diagnostics  market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the Cancer Diagnostics  market.

      Secondary Research

      This research study involved the wide use of secondary sources, directories, databases such as Dun & Bradstreet, Bloomberg Businessweek, Factiva, whitepapers, and companies’ house documents. Secondary research was undertaken to identify and collect information for this extensive, technical, market-oriented, and commercial study of the Cancer Diagnostics  market. It was also used to obtain important information about the top players, market classification, and segmentation according to industry trends to the bottom-most level, geographic markets, and key developments related to the market. A database of the key industry leaders was also prepared using secondary research.

      Primary Research

      In the primary research process, various supply- and demand-side sources were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side included industry experts such as CEOs, VPs/Managing Directors, Marketing Heads/Directors and Sales Directors, Marketing/Sales Managers, Regional/Area Sales Managers, Export/Import Heads/Managers, and Other Cancer Diagnostics  Market Related Personnel from various companies and organizations operating in the Cancer Diagnostics  market. Primary sources from the demand side included Law Enforcement Agencies Vice Presidents,C-level Executives, Department Heads, Enterprises, Individuals, Supply Management Team of Hospitals, Clinic Personnel, and Laboratory Technicians.

      Breakdown of Primary Interviews

      Cancer Diagnostics Market Size, and Share

      Note 1: C-level primaries include CEOs, COOs, CTOs, and VPs.
      Note 2: Other primaries include sales, marketing, and product managers.
      Note 3: Companies are classified into tiers based on their total revenue. As of 2025: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      Both top-down and bottom-up approaches were used to estimate and validate the total size of the Cancer Diagnostics  market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

      Cancer Diagnostics Market : Top-Down and Bottom-Up Approach

      Cancer Diagnostics Market Top Down and Bottom Up Approach

      Data Triangulation

      The entire market was split into two segments when the market size was determined. Data triangulation and market breakdown processes were used where necessary to complete the entire market engineering process and arrive at precise statistics for all segments.

      Approach to derive the market size and estimate market growth.

      Using secondary data from paid and unpaid sources, the market rankings for the major players were determined following a thorough analysis of their sales of Cancer Diagnostics . Due to data restrictions, the revenue share in certain cases was determined after a thorough analysis of the product portfolio of big corporations and their individual sales performance. This information was verified at each stage by in-depth interviews with professionals in the field.

      Market Definition

      Cancer diagnostics refers to the tests, technologies, and procedures used to detect, diagnose, characterize, and monitor cancer, enabling early detection, accurate diagnosis, treatment selection, and disease monitoring. The market includes imaging, molecular diagnostics, biopsy-based testing, immunohistochemistry (IHC), next-generation sequencing (NGS), liquid biopsy, and companion diagnostics, serving hospitals, diagnostic laboratories, cancer centers, and research institutes.

      Key Stakeholders

      • Diagnostic test and kit manufacturers
      • Medical device and imaging equipment manufacturers
      • Molecular diagnostics and genomics companies
      • Hospitals and healthcare systems
      • Diagnostic laboratories (clinical and reference laboratories)
      • Cancer centers and oncology clinics
      • Physicians (oncologists, pathologists, radiologists, and primary care physicians)
      • Academic and research institutes
      • Pharmaceutical and biotechnology companies (companion diagnostics and precision medicine)
      • Contract research organizations (CROs)
      • Government and public health agencies
      • Regulatory authorities
      • Health insurance providers and payers
      • Patients and patient advocacy organizations
      • Distributors and healthcare suppliers

      Report Objectives

      • To describe, analyze, and forecast the Cancer Diagnostics  market, by product, type, application, technology, end user, and region.
      • To describe and forecast the Cancer Diagnostics  market for key regions, namely, North America, Europe, the Asia Pacific, Latin America and Middle East and Africa
      • To provide detailed information regarding drivers, restraints, opportunities, and challenges influencing the growth of the Cancer Diagnostics  market
      • To strategically analyze the ecosystem, regulations, patenting trend, value chain, Porter’s five forces, and prices pertaining to the market under study
      • To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall market
      • To analyze market opportunities for stakeholders and provide details of the competitive landscape for market players
      • To profile key players and comprehensively analyze their market shares and core competencies2 in the Cancer Diagnostics  market
      • To analyze competitive developments such as collaborations, acquisitions, product launches, expansions, and R&D activities in the Cancer Diagnostics  market

      Available customizations:

      With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the report:

      Company Information

      • Detailed analysis and profiling of additional market players (up to 5)

      Product Analysis

      • Product matrix, which gives a detailed comparison of the product portfolios of each company

      Geographic Analysis

      • Further breakdown of the Rest of Asia Pacific Cancer Diagnostics  market into Vietnam, New Zealand, and others.
      • Further breakdown of the Rest of Latin America Cancer Diagnostics  market into Columbia, Chile, Ecuador, and others.
      • Further breakdown of the Rest of Europe Cancer Diagnostics  market into Belgium, Russia, Netherlands, Switzerland, and others.
       

       

      Get the Full Cancer Diagnostics Market Report

      Full forecast, segment splits, and company analysis for all Cancer Diagnostics Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status